SAGE - Sage Therapeutics Inc Stock Price, Fair Value and News

$6.56+0.18 (+2.82%)

Delayed as of 15 May 2025, 02:04 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SAGE Price Action

Last 7 days

-6.4%

Last 30 days

-13.8%

Last 90 days

-11.1%

Trailing 12 Months

-46.8%

SAGE RSI Chart

SAGE Valuation

Market Cap

399.5M

Price/Earnings (Trailing)

-1.13

Price/Sales (Trailing)

8.43

Price/Free Cashflow

-1.28

SAGE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SAGE Fundamentals

SAGE Revenue

Revenue (TTM)

47.4M

Rev. Growth (Yr)

77.97%

Rev. Growth (Qtr)

9.73%

SAGE Earnings

Earnings (TTM)

-354.4M

Earnings Growth (Yr)

42.65%

Earnings Growth (Qtr)

35.04%

SAGE Profitability

Operating Margin

96.87%

Return on Equity

-86.47%

Return on Assets

-75.46%

Free Cashflow Yield

-77.87%

SAGE Investor Care

Shares Dilution (1Y)

4.05%

Diluted EPS (TTM)

-5.8

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	47.4M	0	0	0
2024	91.1M	97.2M	106.4M	41.2M
2023	9.4M	10.4M	11.3M	86.5M
2022	6.3M	6.2M	6.5M	7.7M
2021	837.2M	560.3M	283.3M	6.3M
2020	7.9M	8.9M	561.6M	1.1B
2019	0	62.5M	34.7M	6.9M
2018	0	0	0	90.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Barry E. Greene
WEBSITE	sagerx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	689

Sage Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sage Therapeutics Inc? What does SAGE stand for in stocks?

SAGE is the stock ticker symbol of Sage Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sage Therapeutics Inc (SAGE)?

As of Wed May 14 2025, market cap of Sage Therapeutics Inc is 399.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SAGE stock?

You can check SAGE's fair value in chart for subscribers.

Is Sage Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SAGE is over valued or under valued. Whether Sage Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sage Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAGE.

What is Sage Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 14 2025, SAGE's PE ratio (Price to Earnings) is -1.13 and Price to Sales (PS) ratio is 8.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAGE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sage Therapeutics Inc's stock?

In the past 10 years, Sage Therapeutics Inc has provided -0.199 (multiply by 100 for percentage) rate of return.